Jing Diamond Biomedical and Tai Zhong join forces to seize the NT$7 billion lipolysis market opportunity
Jing Diamond Biomedical (hereinafter referred to as “Jing Diamond Biomedical”, stock code: 6815) held a launch event for the Ronkyla chin filler injection today (March 4th). General Manager Xie Jiaxian stated that Ronkyla is one of only two legally available drugs in Taiwan for eliminating double chins. Since its launch, it has received high praise. With the lifting of mask mandates, there has been a significant increase in demand for facial aesthetics, particularly concerning the lower face. Based on international experiences, the annual market size for lipolysis or fat reduction in Taiwan could reach NT$700 million. Ronkyla chin filler injections are expected to become a significant contributor to the company’s growth.
Today’s event featured artist Lin Lifen as the product endorser, along with the inventor of Ronkyla, Dr. Gao Minxiong, Chairman of a leading biotechnology consulting company, Ronkyla chin filler injection general agent, Chairman Xu Huanqing of Tai Zhong Biotech, and hundreds of medical aesthetics and dermatologists for sharing and exchange.
Ronkyla chin filler injections utilize a substance that can dissolve and eliminate fat cells, promoting natural metabolism after dissolution. Compared to traditional surgical procedures and liposuction, lipolysis needle products have lower risks and shorter recovery periods, leading to rapid growth in demand in the global medical aesthetics market in recent years.
Ronkyla chin filler injection is the only domestically branded new drug approved by the TFDA for eliminating double chins. Currently, there is only one imported competitor on the market, Belkyra. Due to Ronkyla’s ingredient composition containing deoxycholic acid, it is less prone to swelling and pain, and it provides excellent fat elimination results, making it highly competitive.
Physicians present at the event noted that the cause of double chins is not solely due to obesity. Apart from aging and loosening skin, modern individuals spending extended periods looking down at their phones can also develop double chins, even among those with slim figures. Therefore, with the end of the COVID-19 pandemic and the mask mandates lasting for over three years, nearly half of the recent inquiries at medical aesthetics clinics are for treatments targeting the lower facial area.
Physicians also emphasized that when choosing medical aesthetic treatments, consumers must first select qualified medical institutions and products evaluated by professional physicians, especially confirming whether they have TFDA market approval to ensure safety.
Regarding the sales strategy for Ronkyla chin filler injections, Xie Jiaxian stated that Jing Diamond Biomedical has already signed procurement contracts with major domestic medical aesthetic groups. Additionally, they will continue to advocate correct concepts of lipolysis and fat reduction through online and social media platforms. Based on international experiences, Xie Jiaxian believes that the annual market size for lipolysis or fat reduction in Taiwan is at least NT$700 million. With Ronkyla’s competitive advantage, there is an opportunity to capture a considerable market share, not only contributing to Jing Diamond Biomedical’s performance but also benefiting the operation of the general agent, Tai Zhong Biotech, simultaneously.